Click here to enlarge.
PDB ID:
Entry in NMR Restraints Grid
Validation report in NRG-CING
Chem Shift validation: AVS_full
BMRB Entry DOI: doi:10.13018/BMR36284
MolProbity Validation Chart
NMR-STAR file interactive viewer.
NMR-STAR v3 text file.
XML gzip file.
RDF gzip file.
All files associated with the entry
Citation: Imai, S.; Yokomizo, T.; Kofuku, Y.; Shiraishi, Y.; Ueda, T.; Shimada, I.. "Structural equilibrium underlying ligand-dependent activation of beta2-adrenoreceptor" Nat. Chem. Biol. 16, 430-439 (2020).
PubMed: 31959965
Assembly members:
entity_1, polymer, 336 residues, 38557.980 Da.
Natural source: Common Name: Human Taxonomy ID: 9606 Superkingdom: Eukaryota Kingdom: Metazoa Genus/species: Homo sapiens
Experimental source: Production method: recombinant technology Host organism: Spodoptera frugiperda
Data type | Count |
15N chemical shifts | 19 |
1H chemical shifts | 19 |
Entity Assembly ID | Entity Name | Entity ID |
---|---|---|
1 | entity_1 | 1 |
Entity 1, entity_1 336 residues - 38557.980 Da.
1 | GLY | THR | GLN | GLN | ARG | ASP | GLU | VAL | TRP | VAL | ||||
2 | VAL | GLY | MET | GLY | ILE | VAL | MET | SER | LEU | ILE | ||||
3 | VAL | LEU | ALA | ILE | VAL | PHE | GLY | ASN | VAL | LEU | ||||
4 | VAL | ILE | THR | ALA | ILE | CYS | LYS | PHE | GLU | ARG | ||||
5 | LEU | GLN | THR | VAL | THR | ASN | TYR | PHE | ILE | THR | ||||
6 | SER | LEU | ALA | VAL | ALA | ASP | LEU | VAL | MET | GLY | ||||
7 | LEU | ALA | VAL | VAL | PRO | PHE | GLY | ALA | ALA | HIS | ||||
8 | ILE | LEU | THR | LYS | THR | TRP | THR | PHE | GLY | ASN | ||||
9 | PHE | TRP | CYS | GLU | PHE | TRP | THR | SER | ILE | ASP | ||||
10 | VAL | LEU | CYS | VAL | THR | ALA | SER | ILE | TRP | THR | ||||
11 | LEU | CYS | VAL | ILE | ALA | VAL | ASP | ARG | TYR | PHE | ||||
12 | ALA | ILE | CYS | SER | PRO | PHE | LYS | TYR | GLN | SER | ||||
13 | LEU | LEU | THR | LYS | CYS | LYS | ALA | ARG | VAL | ILE | ||||
14 | ILE | LEU | MET | VAL | TRP | ILE | VAL | SER | GLY | LEU | ||||
15 | THR | SER | PHE | LEU | PRO | ILE | GLN | MET | HIS | TRP | ||||
16 | TYR | ARG | ALA | THR | HIS | GLN | GLU | ALA | ILE | ASN | ||||
17 | CYS | TYR | ALA | GLU | GLU | THR | CYS | CYS | ASP | PHE | ||||
18 | PHE | THR | ASN | GLN | ALA | TYR | ALA | ILE | ALA | SER | ||||
19 | SER | ILE | VAL | SER | PHE | TYR | VAL | PRO | LEU | VAL | ||||
20 | ILE | MET | VAL | PHE | VAL | TYR | SER | ARG | VAL | PHE | ||||
21 | GLN | GLU | ALA | LYS | ARG | GLN | LEU | GLN | LYS | ILE | ||||
22 | ASP | LYS | SER | GLU | GLY | ARG | PHE | HIS | VAL | GLN | ||||
23 | ASN | VAL | SER | GLN | VAL | GLU | GLN | ASP | GLY | ARG | ||||
24 | THR | GLY | HIS | GLY | HIS | ARG | ARG | SER | SER | LYS | ||||
25 | PHE | ALA | CYS | LYS | GLU | HIS | LYS | ALA | LEU | LYS | ||||
26 | THR | LEU | GLY | ILE | ILE | MET | GLY | THR | PHE | THR | ||||
27 | LEU | CYS | TRP | LEU | PRO | PHE | PHE | ILE | VAL | ASN | ||||
28 | ILE | VAL | HIS | VAL | ILE | GLN | ASP | ASN | LEU | ILE | ||||
29 | ARG | LYS | GLU | VAL | TYR | ILE | LEU | LEU | ASN | TRP | ||||
30 | ILE | GLY | TYR | VAL | ASN | SER | GLY | PHE | ASN | PRO | ||||
31 | LEU | ILE | TYR | SER | ARG | SER | PRO | ASP | PHE | ARG | ||||
32 | CYS | ALA | PHE | GLN | GLU | LEU | LEU | ALA | ALA | ARG | ||||
33 | ARG | SER | SER | VAL | LYS | ALA | HIS | HIS | HIS | HIS | ||||
34 | HIS | HIS | HIS | HIS | HIS | HIS |
sample_1: HEPES 20 ± 1 mM; beta 2 adrenergic receptor (A59C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_10: HEPES 20 ± 1 mM; ascorbate 1 ± 0.1 mM; beta 2 adrenergic receptor (I334C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_11: HEPES 20 ± 1 mM; beta 2 adrenergic receptor (I334C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_2: HEPES 20 ± 1 mM; ascorbate 1 ± 0.1 mM; beta 2 adrenergic receptor (A59C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_3: HEPES 20 ± 1 mM; beta 2 adrenergic receptor (T136C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_4: HEPES 20 ± 1 mM; ascorbate 1 ± 0.1 mM; beta 2 adrenergic receptor (T136C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_5: HEPES 20 ± 1 mM; beta 2 adrenergic receptor (N148C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_6: HEPES 20 ± 1 mM; ascorbate 1 ± 0.1 mM; beta 2 adrenergic receptor (N148C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_7: HEPES 20 ± 1 mM; beta 2 adrenergic receptor (L266C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_8: HEPES 20 ± 1 mM; ascorbate 1 ± 0.1 mM; beta 2 adrenergic receptor (L266C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_9: HEPES 20 ± 1 mM; beta 2 adrenergic receptor (I334C-MTSL), [2,3,3-2H,15N]-Leu, 100 ± 10 uM; H2O 95%; D2O, [U-2H], 5%
sample_conditions_1: ionic strength: 0 mM; pH: 6.5; pressure: 1 atm; temperature: 298 K
Name | Sample | Sample state | Sample conditions |
---|---|---|---|
2D 1H-15N HSQC | sample_1 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_2 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_3 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_4 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_5 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_6 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_7 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_8 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_9 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_10 | isotropic | sample_conditions_1 |
2D 1H-15N HSQC | sample_11 | isotropic | sample_conditions_1 |
CNS, Brunger A. T. et.al. - refinement
TopSpin, Bruker Biospin - chemical shift assignment, peak picking
X-PLOR NIH, Schwieters, Kuszewski, Tjandra and Clore - structure calculation
Download HSQC peak lists in one of the following formats:
CSV: Backbone
or all simulated peaks
SPARKY: Backbone
or all simulated peaks